Participants 42 92 4
patients with moderate-to-severe plaque psoriasis:
Participants 329 452 7
. 197 patients with moderate-to-severe plaque psoriasis were randomized to tofacitinib 2, 5 or 15â€‰mg twice daily, or plac
